You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK)聚焦創新醫藥主業 擬約1.22億元退出尼科公司參股項目
格隆匯 05-26 19:40

格隆匯5月26日丨麗珠醫藥(01513.HK)發佈公告,2020年5月23日,集團、餘永毅(尼科公司實際控制人及創始人)、紫金中浩(浙江)投資有限公司、吳光明等尼科公司其他股東(上述各方統稱為“售股股東”)及江蘇尼科醫療器械有限公司與Genesis Medtech Investment(HK)Limited簽署了《關於江蘇尼科醫療器械有限公司之股權轉讓協議》。根據《股權轉讓協議》,Genesis同意以人民幣51,592.50萬元或等值美元受讓售股股東所持有的尼科公司80%的股權。截至該公告日,公司持有尼科公司19.99%股權,公司出售持有尼科公司19.99%股權的對價約為人民幣12,150.75萬元。

公告表示,尼科公司為公司參股企業,其主要從事醫療器械產品的生產及銷售,本次出售股權有效地實現了公司已投參股項目的退出,使公司更加聚焦創新醫藥主業。經初步測算,扣除公司的投資成本、税費等相關費用後本次出售股權預計增加公司歸屬於母公司股東的淨利潤約為人民幣8,523.99萬元,對公司本年度財務狀況和經營成果不構成重大影響,最終可實現的淨利潤將以公司2020年度審計報告為準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account